Introduction
Changes in myocardial susceptibility to infarction by DM
Species | DM | Index ischemia | First author | Journal | ||
---|---|---|---|---|---|---|
type | duration | min | type | |||
Infarct size enlargement
| ||||||
Dog | 2 | 75 d | 120 | regional, vivo | Forrat | Cardiovasc Res 1993 |
Rat (SD) | 1 | 8 d | 25 | regional, vivo | Marfella | Diabetologia 2002 |
Rat (SD) | 1 | 8 d | 25 | regional, vivo | Di Filippo | Diabetes 2005 |
Rat (SD) | 1 | 30 d | 30 | global, vitro | Thirunavukkarasu | Free Radic Biol Med 2007 |
Rat (Wistar) | 1 | 2 w | 30 | regional, vivo | Xiao | J Pharmacol Exp Ther 2004 |
Rat (Zucker obese) | 2 | 30 | regional, vivo | Jordan | J Pharmacol Exp Ther 2003 | |
Rat (Zucker obese) | 2 | (10-12 w old) | 30 | regional, vivo | Katakam | Am J Physiol 2007 |
Rat (Zucker diabetic fatty) | 2 | (10-12 w old) | 30 | regional, vivo | Yue | Diabetes 2005 |
Rat (Zucker diabetic fatty) | 2 | (12-16 w old) | 30 | regional, vivo | La Bonte | Am J Physiol 2008 |
Rat (OLETF) | 2 | (25-30 w old) | 20 | regional, vivo | Miki | Diabetes 2009 |
Rat (OLETF) | 2 | (25-30 w old) | 20 | regional, vivo | Hotta | Circ Res 2010 |
Mice | 1 | 8 d | 25 | regional, vivo | Marfella | Diabetes 2004 |
Mice | 1 | 4 w | 60 | regional, vivo | Liu | Diabetes 2005 |
Mice (ob/ob) | 2 | (8-10 w old) | 30 | regional, vivo | Bouhidel | Am J Physiol 2008 |
Mice (ob/ob) | 2 | (8-10 w old) | 30 | regional, vivo | Calvert | Diabetes 2008 |
Mice (ob/ob) | 2 | (10-12 w old) | 30 | regional, vivo | Zhu | J Cell Mol Med 2011 |
Mice (KK-Ay) | 2 | (6 w old) | 40 | regional, vivo | Honda | J Mol Cell Cardiol 2008 |
Infarct size reduction
| ||||||
Rabbit (NZ) | 1 | 8 w | 30 | regional, vivo | Hadour | J Mol Cell Cardiol 1998 |
Rat (SD) | 1 | 2 w | 30 | regional, vivo | Ma | N-S Arch Pharmacol 2006 |
Rat (Wistar) | 2 | 11-12 m | 30, 45 | regional, vivo | Liu | Circulation 1993 |
Rat (Wistar) | 1 | 1 w | 30 | regional, vivo | Ravingerová | Mol Cell Biochem 2003 |
Rat (Wistar) | 1 | 4 w | 30 | regional, vivo | Xu | Exp Mol Pathol 2004 |
Rat (Wistar) | 1 | 6 w | 30 | regional, vivo | Galagudza | Neurosci Behav Physiol 2007 |
Rat (Wistar) | 2 | 10-12 w | 30 | global, vitro | Kravchuk | Exp Diabetes Res 2011 |
Rat (Wistar-Kyoto) | 2 | 9 m | 40 | regional, vitro | Mozaffari | Hypertension 2003 |
Rat (Zucker diabetic fatty) | 2 | (16 w old) | 50 | regional, vitro | Kristiansen | Diabetologia 2004 |
Rat (Goto-Kakizaki) | 2 | (16 w old) | 50 | regional, vitro | Kristiansen | Diabetologia 2004 |
Rat (Goto-Kakizaki) | 2 | (16 w old) | 45 | regional, vitro | Kristiansen | Diabetologia 2011 |
No change in infarct size
| ||||||
Dog | 1 | 3 w | 60 | regional, vivo | Kersten | Am J Physiol 2000 |
Dog | 1 | 3 w | 60 | regional, vivo | Kersten | Am J Physiol 2001 |
Rabbit (NZ) | 1 | 10-16 w | 30 | regional, vivo | Vogel | Circ Res 1988 |
Rabbit (NZ) | 1 | 4-5 w | 60 | regional, vivo | Nieszner | Exp Clin Endocrinol Diabetes 2002 |
Rabbit (NZ white) | 1 | 5-6 w | 30 | regional, vivo | Ebel | Pflügers Arch 2003 |
Rat (SD) | 1 | 6 w | 30 | regional, vivo | Ma | N-S Arch Pharmacol 2006 |
Rat (SD) | 1 | 2 w | 30 | regional, vivo | Gross | Diabetes 2007 |
Rat (SD) | 1 | 4 w, 8 w | 30 | global, vitro | Shi-Ting | Biomed Pharmacother 2010 |
Rat (SD) | 1 | 4-5 w | 30 | regional, vivo | Drenger | Anesthesiology 2011 |
Rat (SD) | 1 | 4 w | 30 | global, vitro | Okazaki | J Mol Cell Cardiol 2011 |
Rat (Wistar) | 1 | 8 w | 30 | regional, vitro | Joyeux | Cardiovasc Res 1999 |
Rat (Wistar) | 1 | 8 w | 30 | regional, vivo | Ravingerová | Mol Cell Biochem 2003 |
Rat (Wistar) | 1 | 20 w | 30 | regional, vivo | Xu | Exp Mol Pathol 2004 |
Rat (Wistar) | 1 | 4 w | 25 | global, vitro | Ghaboura | Basic Res Cardiol 2011 |
Rat (Goto-Kakizaki) | 2 | 35 | regional, vitro | Tsang | Diabetes 2005 | |
Rat (Goto-Kakizaki) | 2 | 35 | regional, vitro | Bhamra | Basic Res Cardiol 2008 | |
Rat (Goto-Kakizaki) | 2 | (12 w old) | 35 | regional, vivo | Bulhak | Am J Physiol 2009 |
Rat (Goto-Kakizaki) | 2 | 30 | regional, vivo | Matsumoto | Cardiovasc Drug Ther 2009 | |
Mice | 1 | 2 w | 30 | global, vitro | Przyklenk | Antioxid Redox Signal 2011 |
Mice (ob/ob) | 2 | (12-14 w old) | 30 | global, vitro | Przyklenk | Antioxid Redox Signal 2011 |
Species | Duration of hyperglycemia | Blood sugar (mg/dl) | Index ischemia | First author | Journal | |
---|---|---|---|---|---|---|
min | type | |||||
Hyperglycemia
| ||||||
Infarct size enlargement
| ||||||
Dog | before I | 585 vs. 71 | 60 | regional, vivo | Kersten | Am J Physiol 1998 |
Rabbit (NZ white) | throughout | 594 vs. 99 | 30 | regional, vitro | Wong | J Diabetes Complications 2011 |
Rat (SD) | during I | 324 vs 85 | 30 | regional, vivo | Su | Am J Physiol 2007 |
No change in infarct size
| ||||||
Dog | before I | 310 vs. 71 | 60 | regional, vivo | Kersten | Am J Physiol 1998 |
Dog | before I | 310 vs. 75 | 60 | regional, vivo | Kersten | Am J Physiol 2001 |
Dog | before I | 316, 579 vs. 78 | 60 | regional, vivo | Kehl | Anesthesiology 2002 |
Dog | before I | 307 vs 83 | 60 | regional, vivo | Gu | Anesthesiology 2008 |
Rabbit (NZ white) | before and during I | 660 vs. 185 | 30 | regional, vivo | Ebel | Pflugers Arch 2003 |
Rabbit (NZ white) | before I | 257 vs 124 | 30 | regional, vivo | Amour | Anesthesiology 2010 |
Rabbit (NZ white) | before and during I | 338 vs 142 | 40 | regional, vivo | Raphael | J Cardiovasc Pharmacol 2010 |
Rat (SD) | before and during I | 360 vs 112 | 30 | regional, vivo | Ichinomiya | Cardiovasc Diabetol 2012 |
Rat (Wistar) | before and during I | >400 vs. 121 | 25 | regional, vivo | Weber | Eur J Pharmacol 2008 |
Rat (Wistar) | before and during I | 459 vs 128 | 25 | regional, vivo | Huhn | Br J Anaesth 2008 |
Rat (Wistar) | before and during I | 355 vs 89 | 30 | regional, vivo | Matsumoto | Cardiovasc Diabetol 2012 |
Metabolic syndrome
| ||||||
Infarct size enlargement
| ||||||
Rat (Wistar) | Western diet for 16 w | 95 vs 87 | 40 | regional, vitro | du Toit | Am J Physiol 2008 |
No change in infarct size
| ||||||
Rat (SD) | high fat diet for 13 w | 160 vs 144 | 45 | regional, vivo | Thim | Clin Sci (Lond) 2006 |
Rat (WOKW) | (28 w old) | 105 vs. ? | 30 | regional, vivo | Wagner | J Cardiovasc Pharmacol 2008 |
Experimental studies
Clinical studies
Defects in intracellular protective signaling in DM hearts
Species | DM | PC stimuli | First author | Journal | |
---|---|---|---|---|---|
type | duration | ||||
Preserved protection
| |||||
PC
| |||||
Rat (SD) | 1 | 4 w | 3x 5I5R | Shi-Ting | Biomed Pharmacother 2010 |
Rat (Wistar) | 2 | 11-12 m | 3x 5I5R | Liu | Circulation 1993 |
Rat (Wistar) | 1 | 6 w | LiCl 20 mM, IND 1 μM, SB 3 μM | Yadav | Mol Cell Biochem 2010 |
Rat (Zucker diabetic fatty) | 2 | (10-12 w old) | Rosiglitazone 3 mg/kg for 1 week | Yue | Diabetes 2005 |
Rat (OLETF) | 2 | (25-30 w old) | SB 1.2 mg/kg | Miki | Diabetes 2009 |
Rat (Goto-Kakizaki) | 2 | 3x 5I10R | Tsang | Diabetes 2005 | |
Rat (Goto-Kakizaki) | 2 | (12 w old) | WY 1 mg/kg | Bulhak | Am J Physiol 2009 |
Rat (Goto-Kakizaki) | 2 | olprinone 10 μg/kg | Matsumoto | Cardiovasc Drug Ther 2009 | |
Mice (ob/ob) | 2 | (8-10 w old) | Metformin 125 μg/kg | Calvert | Diabetes 2008 |
Mice (KK-Ay) | 2 | (6 w old) | Pioglitazone 25 mg/kg for 2 week | Honda | J Mol Cell Cardiol 2008 |
PostC
| |||||
Rat (SD) | 1 | 2 w | SB 0.6 mg/kg | Gross | Diabetes 2007 |
Rat (Wistar) | 1 | 4 w | SB 3 μM | Ghaboura | Basic Res Cardiol 2011 |
Rat (OLETF) | 2 | (25-30 w old) | BIO 0.08 mg/kg | Hotta | Circ Res 2010 |
Rat (Goto-Kakizaki) | 2 | Metformin 50 μM | Bhamra | Basic Res Cardiol 2008 | |
Mice (ob/ob) | 2 | (8-10 w old) | Metformin 125 μg/kg | Calvert | Diabetes 2008 |
Impaired protection
| |||||
PC
| |||||
Dog | 1 | 3 w | 4x 5I5R | Kersten | Am J Physiol 2000 |
Dog | 1 | 3 w | Diazoxide 2.5 mg/kg | Kersten | Am J Physiol 2001 |
Rabbit (NZ) | 1 | 4-5 w | 3x 2I2R | Nieszner | Exp Clin Endocrinol Diabetes 2002 |
Rat (SD) | 1 | 8 w | 3x 5I5R | Wang | Biomedicine Aging Pathol 2011 |
Rat (Wistar) | 1 | 6 w | 5I5R | Galagudza | Neurosci Behav Physiol 2007 |
Rat (Wistar) | 1 | 6 w | 4x 5I5R | Yadav | Mol Cell Biochem 2010 |
Rat (Wistar) | 2 | 10-12 w | Metformin 200 mg/kg for 3 days | Kravchuk | Exp Diabetes Res 2011 |
Rat (Zucker obese) | 2 | (10-12 w old) | 5I5R, Diazoxide 10 mg/kg | Katakam | Am J Physiol 2007 |
Rat (Zucker diabetic fatty) | 2 | (16 w old) | 4x 2I3R | Kristiansen | Diabetologia 2004 |
Rat (OLETF) | 2 | (25-30 w old) | EPO 5000 U/kg | Miki | Diabetes 2009 |
Rat (OLETF) | 2 | (25-30 w old) | EPO 5000 U/kg, DADLE 1 mg/kg | Hotta | Circ Res 2010 |
Rat (Goto-Kakizaki) | 2 | (16 w old) | 4x 2I3R | Kristiansen | Diabetologia 2004 |
Rat (Goto-Kakizaki) | 2 | 5I10R, 2x 5I10R | Tsang | Diabetes 2005 | |
Rat (Goto-Kakizaki) | 2 | (16-18 w old) | EPO 5000 U/kg | Miki | Diabetes 2009 |
Rat (Goto-Kakizaki) | 2 | isoflurane 1.0% | Matsumoto | Cardiovasc Drug Ther 2009 | |
PostC
| |||||
Rat (SD) | 1 | 2 w | Morphine 0.3 mg/kg | Gross | Diabetes 2007 |
Rat (SD) | 1 | 4-5 w | 3x 20sR20sI, sevoflurane 1.0 MAC | Drenger | Anesthesiology 2011 |
Rat (Wistar) | 1 | 4 w | Darbopoetin alpha 5 μg/kg | Ghaboura | Basic Res Cardiol 2011 |
Mice | 1 | 2 w | 3x 10sR10sI, 6x 10sR10sI | Przyklenk | Antioxid Redox Signal 2011 |
Mice (ob/ob) | 2 | (8-10 w old) | 6x 10sR10sI | Bouhidel | Am J Physiol 2008 |
Mice (ob/ob) | 2 | (12-14 w old) | 3x 10sR10sI, 6x 10sR10sI | Przyklenk | Antioxid Redox Signal 2011 |
Mice (ob/ob) | 2 | (10-12 w old) | 6x 10sR10sI | Zhu | J Cell Mol Med 2011 |
Mice (KK-Ay) | 2 | (6 w old) | Pioglitazone 25 mg/kg | Honda | J Mol Cell Cardiol 2008 |
Late PC
| |||||
Rabbit (NZ white) | 1 | 5-6 w | 5I24hR | Ebel | Pflugers Arch 2003 |
Species | Duration of Blood sugar | PC stimuli | First author | Journal | |
---|---|---|---|---|---|
hyperglycemia | (mg/dl) | ||||
Hyperglycemia
| |||||
Preserved protection
| |||||
PC
| |||||
Dog | before I | 397 | Diazoxide 5.0 mg/kg | Kersten | Am J Physiol 2001 |
Dog | before I | 291 | Isoflurane 1.0 MAC | Kehl | Anesthesiology 2002 |
Rat (SD) | before and during I | 360 | Fasudil 0.5 mg/kg | Ichinomiya | Cardiovasc Diabetol 2012 |
Rat (Wistar) | before and during I | 446 | Sevoflurane 1.0 MAC + CysA 5 mg/kg | Huhn | Br J Anaesth 2008 |
Rat (Wistar) | before and during I | 343, 447 | MIL 30 μg/kg, LEVO 100 μg/kg | Matsumoto | Cardiovasc Diabetol 2012 |
Impaired protection
| |||||
PC
| |||||
Dog | before I | 296 | 4x 5I5R | Kersten | Am J Physiol 1998 |
Dog | before I | 329 | Diazoxide 2.5 mg/kg | Kersten | Am J Physiol 2001 |
Dog | before I | 581, 558 | Isoflurane 0.5, 1.0 MAC | Kehl | Anesthesiology 2002 |
Dog | before I | 293 | 4x 5I5R | Gu | Anesthesiology 2008 |
Rabbit (NZ white) | before I | 281 | Isoflurane 1.0 MAC | Amour | Anesthesiology 2010 |
Rat (Wistar) | before I or during I | >400 | Desflurane 1.0 MAC | Weber | Eur J Pharmacol 2008 |
PostC
| |||||
Rabbit (NZ white) | before and during I | 353 | Isoflurane 1.0 MAC | Raphael | J Cardiovasc Pharmacol 2010 |
Rat (SD) | before and during I | 360 | Diazoxide 10 mg/kg, Fasudil 0.15 mg/kg | Ichinomiya | Cardiovasc Diabetol 2012 |
Rat (Wistar) | before and during I | 445, 441 | Sevoflurane 1.0 MAC, CysA 5 mg/kg | Huhn | Br J Anaesth 2008 |
Metabolic syndrome
| |||||
Impaired protection
| |||||
PostC
| |||||
Rat (WOKW) | (28 w old) | 105 | 3x 30sI30sR | Wagner | J Cardiovasc Pharmacol 2008 |
First author | % of DM | Age | Protocol | Results | |||
---|---|---|---|---|---|---|---|
ST resolution | LV function | Enzyme release | Infarct size | ||||
Ischemic PostC
| |||||||
Staat | 20 vs. 13 | 58 vs. 56 | 4x 60sR/I | Improved | N/A | Reduced (peak, AUC) | N/A |
Laskey | N/A | 58 vs. 58 | 2x 90sR/I | Improved | N/A | Nochange (peak) | N/A |
Ma | 38 vs. 45 | 64 vs. 64 | 3x 30sR/I | N/A | Improved WMSI | Reduced (peak) | N/A |
Yang | 26 vs. 28 | 59 vs. 63 | 3x 30sR/I | No change | No change | Reduced (AUC) | Reduced (SPECT, 1w) |
Thibault | 12 vs. 10 | 56 vs. 56 | 4x 60sR/I | N/A | Improved EF, WMSI | Reduced (AUC) | Reduced (SPECT, 6m) |
Laskey | 38 vs. 42 | 60 vs. 58 | 2x 90sR/I | Improved | No change | Reduced (peak) | N/A |
Xue | 21 vs. 29 | 54 vs. 62 | 4x 60sR/I | Improved | Improved EF, WMSI | Reduced (peak, AUC) | Reduced (SPECT, 1w) |
Lønborg | 7 vs. 7 | 61 vs. 62 | 4x 30sR/I | No change | No change | N/A | Reduced (CMR, 3m) |
Sörensson | 25 vs. 17 | 63 vs. 62 | 4x 60sR/I | N/A | No change *1 | No change (AUC) | No change (CMR, 1w) *1 |
Freixa | 23 vs. 17 | 59 vs. 60 | 4x 60sR/I | N/A | No change | No change (peak) | No change (CMR, 1w & 6m) |
Tarantini | 18 vs. 3 | 60 vs. 60 | 4x 60sR/I | No change | No change | No change (AUC) | No change (CMR, 1m) |